If Amgen Inc. and Novartis AG win approval of the calcitonin gene-related peptide (CGRP) inhibitor Aimovig (erenumab) – the PDUFA date is May 17 – the compound's price tag could provide guidance for others with CGRP monoclonal antibodies in their migraine pipelines, such as Alder Biopharmaceutical Inc., with eptinezumab due to yield phase III data this quarter from the PROMISE 2 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 2) trial in chronic migraine.